Article
Biology
Tomonari Kinoshita, Hideki Terai, Tomonori Yaguchi
Summary: This article summarizes the current use of immunotherapies in lung cancer treatment, including immune checkpoint inhibitors, and discusses the future prospects of personalized immunotherapy.
Article
Immunology
Alexandre E. Malek, Melissa Khalil, Ray Hachem, Anne Marie Chaftari, Johny Fares, Ying Jiang, Dimitrios P. Kontoyiannis, Frank Fossella, Patrick Chaftari, Victor E. Mulanovich, George M. Viola, Issam I. Raad
Summary: The study compared the risk of infection in lung cancer patients treated with CPI combined with chemotherapy versus chemotherapy alone, finding no significant difference in infection rates between the two groups, but a trend towards fewer urinary tract infections in the CPI group.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Immunology
Viviane Teixeira L. de Alencar, Amanda B. Figueiredo, Marcelo Corassa, Kenneth J. Gollob, Vladmir Cordeiro C. de Lima
Summary: Lung cancer is the second most common and the most lethal malignancy worldwide, with lung cancer in never smokers accounting for 10-25% of cases. These tumors have a better prognosis but poor response to immune therapy, possibly due to factors like low immunogenicity and constitutive PD-L1 expression.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Bryan Oronsky, Nacer Abrouk, Scott Caroen, Michelle Lybeck, Xiaoning Guo, Xiaohui Wang, Zhongwen Yu, Tony Reid
Summary: For close to 40 years, small-cell lung cancer (SCLC) has been stagnant with no progress or effective treatments. However, between 2018 and 2021, several new drugs were approved, bringing hope to SCLC patients.
Article
Oncology
Li Pang, Mei Xie, Xidong Ma, Aiben Huang, Jialin Song, Jie Yao, Hui Deng, Duchao Zhang, Xuelei Zang, Fangping Ren, Jie Gao, Chongchong Wu, Yuanyong Wang, Xin Zhang, Xinyu Bao, Lei Pan, Xinying Xue
Summary: This study retrospectively analyzed the clinical and imaging data of 704 patients with non-small cell lung cancer who received immunotherapy, and summarized the clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis.
Review
Oncology
Michael Burke, Sawsan Rashdan
Summary: Immune-related adverse events from immunotherapy in NSCLC present challenges in diagnosis and management, requiring interdisciplinary efforts. Future directions may involve identifying potential biomarkers for better recognition of toxicities.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Cong Zhou, Xiaojiao Cheng, Shuiping Tu
Summary: ICIs are revolutionizing cancer immunotherapy, with significant effects on melanoma and NSCLC. In the case of CRC, patients with high immunogenicity benefit from ICIs, while those with low immunogenicity do not. Ongoing clinical trials aim to improve response to ICIs in CRC patients through better selection and combination strategies.
Review
Oncology
Yuxuan Hao, Xiaoye Zhang, Li Yu
Summary: This review discusses the risk factors, pathogenesis, clinical characteristics, diagnosis, grading, and management of immune checkpoint inhibitor-related pneumonitis (ICI-P) in non-small cell lung cancer (NSCLC), as well as the relationship between ICI-P and the efficacy of ICI therapy. In addition, predictive factors for ICI-P are also discussed.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Yanxin Chen, Yunwei Liu, Xiaoliang Xiong, Zhimin Zeng, Daya Luo, Anwen Liu
Summary: Immunotherapy is a promising treatment for malignant tumors, but it may lead to adverse effects on multiple organs. However, there is limited knowledge about these immunotherapy-related adverse effects (irAEs). This study used a mouse model and histopathological methods to comprehensively describe the pathological changes caused by PD-1 inhibitors in multiple organs.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Immunology
Bettina Hoden, David DeRubeis, Margarita Martinez-Moczygemba, Kenneth S. Ramos, Dekai Zhang
Summary: Innate immune response mechanisms play a crucial role in lung cancer immunity and immunotherapy. TLR signaling can modulate the tumor microenvironment and enhance the immune sensitization of tumor cells to treatments.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Emanuele Barabino, Giovanni Rossi, Silvia Pamparino, Martina Fiannacca, Simone Caprioli, Alessandro Fedeli, Lodovica Zullo, Stefano Vagge, Giuseppe Cittadini, Carlo Genova
Summary: The study aims to identify radiomic features that can predict the response to immunotherapy. By analyzing the lesions of patients with advanced non-small cell lung cancer, the study explores the features that predict the response to immune checkpoint inhibitors. The finding shows that 27 features can accurately distinguish the radiologic response to immune checkpoint inhibitors.
Review
Medicine, General & Internal
Dean E. Watkins, Daniel J. Craig, Shahnaz D. Vellani, Ahmad Hegazi, Kaylee J. Fredrickson, Adam Walter, Laura Stanbery, John Nemunaitis
Summary: Cervical cancer is a global public health crisis, but it can be prevented and treated effectively through vaccination and immunotherapeutic agents.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Xiao-Tong Zhang, Nan Ge, Zi-Jian Xiang, Tao Liu
Summary: This study evaluated the incidence of cardiotoxicity related to immune checkpoint inhibitor (ICI) therapies for lung cancer. The results showed that single ICI did not increase the risk of cardiotoxicity compared to chemotherapy, while single ICI plus chemotherapy increased the risk of cardiotoxicity by 67% compared to chemotherapy alone. Combination immunotherapy did not increase the risk of cardiotoxicity compared to single ICI.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Aiben Huang, Yang Xu, Xuelei Zang, Chongchong Wu, Jie Gao, Xiaoli Sun, Mei Xie, Xidong Ma, Hui Deng, Jialin Song, Fangping Ren, Li Pang, Jin Qian, Zhaofeng Yu, Shiyu Wan, Yuanyuan Chen, Lei Pan, Guanglei Zhuang, Sanhong Liu, Xinying Xue
Summary: Immunotherapy is increasingly used in treating NSCLC, but it can lead to a rare and life-threatening event known as CIP. This study found differences in radiological patterns and prognosis between early- and late-onset CIP cases, with early-onset cases having higher CTCAE grades and poorer prognosis compared to late-onset cases. Identifying these differences can help clinicians diagnose and treat CIP more effectively.
Review
Medicine, General & Internal
Yan Yan, Xijia Feng, Chengqiang Li, Toni Lerut, Hecheng Li
Summary: Esophageal cancer, with high incidence and poor prognosis, has two major histological types: squamous cell carcinoma and adenocarcinoma, which differ in their epidemiology and treatment options. Immunotherapy, particularly adjuvant immune checkpoint inhibitors (ICIs), has emerged as a potential treatment for resectable esophageal cancer. Recent clinical trials have shown promising results with ICIs for resectable esophageal cancer, although some concerns remain.
CHINESE MEDICAL JOURNAL
(2022)
Review
Otorhinolaryngology
Gustavo Schvartsman, Nathalia Almeida Pinto, Diana Bell, Renata Ferrarotto
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2019)
Article
Oncology
Gustavo Schvartsman, Andre P. C. D. Carneiro, Renee Z. Filippi, Priya Rao, Pavlos Msaouel
CLINICAL GENITOURINARY CANCER
(2019)
Article
Oncology
Gustavo Schvartsman, Junsheng Ma, Roland L. Bassett, Lauren E. Haydu, Rodabe Navroze Amaria, Patrick Hwu, Michael K. Wong, Wen-Jen Hwu, Adi Diab, Sapna Pradyuman Patel, Michael A. Davies, Nelson Hamerschlak, Hussein Abdul-Hassan Tawbi, Isabella C. Glitza Oliva
Review
Oncology
Larissa Di Villeneuve, Ive Lima Souza, Fernanda Davila Sampaio Tolentino, Renata Ferrarotto, Gustavo Schvartsman
FRONTIERS IN ONCOLOGY
(2020)
Article
Otorhinolaryngology
Gustavo Schvartsman, Diana Bell, Maria Laura Rubin, Michael Tetzlaff, Ehab Hanna, Jiun-Kae Jack Lee, Randal Weber, Jack Phan, Bonnie S. Glisson, Renata Ferrarotto
Summary: Salivary duct carcinoma is a rare and aggressive malignancy with promising targetable alterations found through biomarker studies. This study analyzed tumor and immune biomarkers in SDC patients and found no clinically significant association between biomarkers and survival outcomes. The results suggest additional treatment options and a different immune profile in SDC compared to other subtypes.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Correction
Oncology
Larissa Di Villeneuve, Ive Lima Souza, Fernanda Davila Sampaio Tolentino, Renata Ferrarotto, Gustavo Schvartsman
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Diogo Garcia, Juliana Rodrigues Beal, Daniel Mamere Alvarez, Ricardo Silvestre e Silva Macarenco, Gustavo Schvartsman
Summary: Immune checkpoint inhibitors have significantly improved survival in metastatic melanoma, but pseudoprogression can be a challenge in treatment response assessment. The occurrence and detection of pseudoprogression in superficial lesions need further investigation.
CASE REPORTS IN ONCOLOGY
(2021)
Review
Oncology
Rubens Copia Sperandio, Francinne Luiza Teixeira Tostes, Paulo Vidal Campregher, Vitor Ribeiro Paes, Fernando Moura, Gustavo Schvartsman
Summary: Comprehensive next-generation sequencing panels are crucial for detecting rare gene fusion events, including the rare oncogenic finding of EFGRRAD51 fusion. We present a case of advanced non-small cell lung cancer in a never-smoker young male patient, who showed sustained near complete response to the third-generation EGFR tyrosine-kinase inhibitor, osimertinib. This case highlights the importance of comprehensive molecular testing in the management of NSCLC.
Meeting Abstract
Oncology
Patricia Taranto, Diogo de Brito Sales, Luciano de Melo Pompei, Alessandro Leal, Gustavo Schvartsman, Antonio Carlos Buzaid
Article
Oncology
Francinne T. Tostes, Miguel Zugman, Vitor R. Paes, Gustavo Schvartsman
FRONTIERS IN ONCOLOGY
(2022)
Article
Genetics & Heredity
Francinne T. Tostes, Parisina Fraga Dutra Cabral de Carvalho, Raphael L. C. Araujo, Rodrigo Chaves Ribeiro, Franz Robert Apodaca-Torrez, Edson Jose Lobo, Diogo Bugano Diniz Gomes, Donato Callegaro-Filho, Gustavo Schvartsman, Fernando Moura, Vladimir Schraibman, Alberto Goldenberg, Fernanda Teresa de Lima, Vanderlei Segatelli, Pedro Luiz Serrano Uson Junior
Summary: This paper reviewed the clinical course of 40 patients with SPN from three Brazilian institutions between 2005 and 2020, and analyzed their clinicopathological, genetic, and surgical aspects. Most patients were women, with unspecified symptoms at diagnosis, and the tumors were mainly located in the body and tail of the pancreas. The majority of patients underwent a distal pancreatectomy with sparing splenectomy, and no recurrence has been observed to date.
Article
Medicine, General & Internal
Mariana Henriques Ferreira, Leticia Mello Bezinelli, Fernanda de Paula Eduardo, Marcella Ferreira Gobbi, Luciana Correa, Gustavo Schvartsman
Summary: This article reports a case of a patient with locally advanced cutaneous squamous cell carcinoma who developed oral ulcers and dysphagia after a single dose of cemiplimab. The patient showed significant improvement after appropriate treatment. The article also discusses the clinical outcomes and oral toxicity management of cemiplimab therapy.
EINSTEIN-SAO PAULO
(2022)
Article
Oncology
Pedro Luiz Serrano Uson Junior, Vanessa Montes Santos, Ive Lima Souza, Gustavo Schvartsman, Fernando Cotait Maluf
Letter
Medicine, General & Internal
Gustavo Schvartsman, Rafael A. Kaliks
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Review
Oncology
Gustavo Schvartsman, Patricia Taranto, Isabella C. Glitza, Sanjiv S. Agarwala, Michael B. Atkins, Antonio C. Buzaid
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2019)